The authors describe a serological survey on the prevalence of infectious bovine rhinotracheitis (IBR) among cattle and buffalo (Bubalus bubalis) in three southern states of India. A local isolate of bovine herpesvirus 1 (BHV-I) from an outbreak of the respiratory form of IBR was used as a source of virus antigen in avidin-biotin enzyme-linked immunosorbent assay (ELISA). The overall prevalence of antibodies to BHV-1 in cattle was 50.9%, and in buffalo was 52.5%. Among breeding bulls, 114/120 samples from Tamil Nadu (95%) and 41/99 samples from Karnataka (41.4%) were seropositive. The possible association of IBR with bovine abortions was recorded in 31/56 samples (55.4%) from aborted crossbred cows. However, virus isolation was not performed on these animals. The authors also highlight the economic importance of IBR to the rapidly developing livestock industry in India.

No abstract

The fusion glycoprotein (F protein) of paramyxoviruses plays a vital role in virus-induced cytopathology. To explore the role of the F protein in peste des petits ruminants virus (PPRV)-induced cytopathology, the F protein of PPRV was purified by immunoaffinity chromatography. The purified F protein, when incubated with chicken erythrocytes, caused lysis suggesting that PPRV F protein is a hemolysin. Furthermore, the hemolysis can be inhibited by hyperimmune serum against F protein. The virus-induced cell fusion (syncytia) was also inhibited by the hyperimmune serum against the F protein. In summary, these results indicate that the purified PPRV F protein is biologically active and is involved in virus-induced hemolysis, cell-fusion and the initiation of infection.

Background: African horse sickness (AHS) is a serious viral disease of equids resulting in the deaths of many equids in sub-Saharan Africa that has been recognized for centuries. This has significant economic impact on the horse industry, despite the good husbandry practices. Currently, prevention and control of the disease is based on administration of live attenuated vaccines and control of the arthropod vectors. Results: A total of 29 horses in 2 groups, were vaccinated. Eighteen horses in Group 1 were further divided into 9 subgroups of 2 horses each, were individually immunised with one of 1 to 9 AHS serotypes, respectively. The eleven horses of Group 2 were immunised with all 9 serotypes simultaneously with 2 different vaccinations containing 5 serotypes (1, 4, 7-9) and 4 serotypes (2, 3, 5, 6) respectively. The duration of this study was 12 months. Blood samples were periodically withdrawn for serum antibody tests using ELISA and VNT and for 2 weeks after each vaccination for PCR and virus isolation. After the booster vaccination, these 27 horses seroconverted, however 2 horses responded poorly as measured by ELISA. In Group 1 ELISA and VN antibodies declined between 5 to 7 months post vaccination (pv). Twelve months later, the antibody levels in most of the horses decreased to the seronegative range until the annual booster where all horses again seroconverted strongly. In Group 2, ELISA antibodies were positive after the first booster and VN antibodies started to appear for some serotypes after primary vaccination. After booster vaccination, VN antibodies increased in a different pattern for each serotype. Antibodies remained high for 12 months and increased strongly after the annual booster in 78% of the horses. PCR and virus isolation results remained negative. Conclusions: Horses vaccinated with single serotypes need a booster after 6 months and simultaneously immunised horses after 12 months. Due to the non-availability of a facility in the UAE, no challenge infection could be carried out.

No abstract